Navigation Links
Zydus Pioneers a Breakthrough With LIPAGLYN, India's First NCE to Reach the Market
Date:6/5/2013

MUMBAI, India, June 5, 2013 /PRNewswire/ --

Lipaglyn™ is the first Glitazar to be approved in the world and the first NCE discovered and developed indigenously by an Indian Pharma Company.

The Zydus Group announced a breakthrough in its research efforts with Lipaglyn™ (Saroglitazar), a novel drug targeted at treating Diabetic Dyslipidemia or Hypertriglyceridemia in Type II diabetes, not controlled by statins alone. The drug has been approved for launch in India by the Drug Controller General of India (DCGI). With a novel action that offers lipid and glucose lowering effects in one molecule, Lipaglyn™ is the first Glitazar to be approved anywhere in the world.

Diabetic Dyslipidemia is a condition where a person is diabetic and has elevated levels of the total cholesterol, the "bad" low-density lipoprotein (LDL) cholesterol and the triglycerides and a decrease in the "good" high-density lipoprotein (HDL) cholesterol concentration in the blood. Almost 85 to 97% of all diabetics are estimated to suffer from diabetic dyslipidemia. Lipaglyn - a non-thiazolidinedione, is the first therapy to be approved for this condition.

"Lipaglyn™ provides patients suffering from diabetic dyslipidemia the option of a once-daily oral therapy that has a beneficial effect on both lipid parameters as well as glycemic control," said Mr. Pankaj Patel , Chairman and Managing Director, Zydus Cadila. "It has always been our dream to take a molecule right from the concept stage up to its launch. Today, we have realized this dream. It is an important breakthrough and I would like to dedicate this to all the Indian research scientists in the field of drug discovery," Mr. Patel added.

Discovered by the Zydus Research Centre, the dedicated NCE research arm of the group, Lipaglyn™ is a best-in-class innovation, designed to have a unique cellular mechanism of action. With a predominant affinity to PPAR alpha isoform and moderate affinity to PPAR gamma isoform of PPAR nuclear receptor subfamily, the molecule has shown beneficial effects on lipids and glycemic control without side effects. The IND was submitted in the year 2004.

The New Drug Application for Lipaglyn™ was based on a comprehensive clinical development programme Phase-I, Phase-II and Phase-III clinical trials, spanning eight years. Results from the first Phase III programme with Pioglitazone as a comparator drug in diabetes patients showed that the 4 mg dose of Lipaglyn™ led to a reduction of triglycerides and LDL cholesterol, and an increase in HDL cholesterol and also showed a reduction in Fasting Plasma Glucose and glycosylated haemoglobin (HbA1c) thereby confirming its beneficial effects of both lipid and glycemic control in diabetic patients. Lipaglyn™ is recommended as 4 mg tablets.

About Zydus Cadila

Zydus Cadila is a global pharmaceutical company headquartered in Ahmedabad, India. The group discovers, develops, manufactures and markets a broad range of healthcare therapies.  With 20 discovery research programmes under various stages of clinical development, the group invests 7% of its turnover on research. The Zydus Research Centre has over 400 research scientists engaged in NCE research.


'/>"/>
SOURCE Cadila Healthcare
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Zydus Demonstra Pioneirismo com o Inovador LIPAGLYN, Primeiro NCE da Índia a Entrar no Mercado
2. PAREXEL Honored with 2013 "Partnership Pioneers of the Year" Award
3. Cone Health Pioneers Use of Fabric That Heals
4. Pressure BioSciences Announces Core Technology Breakthrough
5. Novartis Breakthrough Therapy LDK378 shows a marked clinical response in patients with ALK+ non-small cell lung cancer
6. Breakthrough Method for Lipid Analysis in Fecal Material Developed; New Understanding of Diseases/Disorders Related to Gut Function Possible
7. Breakthrough "AffloVest" Greatly Advances Respiratory Care
8. AbbVies Investigational HCV Regimen Receives Breakthrough Therapy Designation from the U.S. Food and Drug Administration
9. Scioderms SD-101 Receives Breakthrough Therapy Designation from FDA for Treatment of Epidermolysis Bullosa
10. Franciscan St. Francis Health is first hospital in nation to implant breakthrough aortic heart valve device
11. Scott & White Hospital - Round Rock first in Central Texas, one of few nationally to perform breakthrough procedure for acid reflux
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Dialysis Devices Global Market - Forecast to 2022" report ... is the treatment method for the patients with kidney failure, ... and excess fluid from the patient,s blood and thus the ... sodium, potassium and chloride in balance. Increasing ...
(Date:6/23/2016)... 23, 2016 Research and Markets ... Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic ... Coating, Parenteral) - Global Forecast to 2021" report ... The global pharmaceutical excipients market is projected to ... of 6.1% in the forecast period 2016 to 2021. ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer care, and ... in the eye of the beholder, according to experts who offered insights and commentary ... of Managed Care. For the full issue, click here . , For the ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are ... with endometriosis. These women need a treatment plan to not only alleviate symptoms ... can help for preservation of fertility and ultimately achieving a pregnancy. The specialists ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the largest ... as the Medical Director of its new Mesquite-Samuell Farm facility. , “We are ... Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published ... unfamiliar with. The article goes on to state that individuals are now more comfortable ... less common operations such as calf and cheek reduction. The Los Angeles area medical ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that ... chosen by their peers for this recognition are considered among the top 2 percent ... special honors as members of this year’s Legal Elite Hall of Fame: Miami ...
Breaking Medicine News(10 mins):